tbuckley/cabot-search huggingface dataset:
Bring Your Own Location Data: Use of Google Smartphone Location History Data for Environmental Health Research
Authors: Perry Hystad, Ofer Amram, Funso Oje, Andrew Larkin, Kwadwo Boakye, Ally Avery, Assefaw Gebremedhin, Glen Duncan
Journal: Environmental Health Perspectives (2022)

Background: Environmental exposures are commonly estimated using spatial methods, with most epidemiological studies relying on home addresses. Passively collected smartphone location data, like Google Location History (GLH) data, may present an opportunity to integrate existing long-term time–activity data. Objectives: We aimed to evaluate the potential use of GLH data for capturing long-term retrospective time–activity data for environmental health research. Methods: We included 378 individuals who participated in previous Global Positioning System (GPS) studies within the Washington State Twin Registry. GLH data consists of location information that has been routinely collected since 2010 when location sharing was enabled within android operating systems or Google apps. We created instructions for participants to download their GLH data and provide it through secure data transfer. We summarized the GLH data provided, compared it to available GPS data, and conducted an exposure assessment for nitrogen dioxide (NO2) air pollution. Results: Of 378 individuals contacted, we received GLH data from 61 individuals (16.1%) and 53 (14.0%) indicated interest but did not have historical GLH data available. The provided GLH data spanned 2010–2021 and included 34 million locations, capturing 66,677 participant days. The median number of days with GLH data per participant was 752, capturing 442 unique locations. When we compared GLH data to 2-wk GPS data (∼1.8 million points), 95% of GPS time–activity points were within 100m of GLH locations. We observed important differences between NO2 exposures assigned at home locations compared with GLH locations, highlighting the importance of GLH data to environmental exposure assessment. Discussion: We believe collecting GLH data is a feasible and cost-effective method for capturing retrospective time–activity patterns for large populations that presents new opportunities for environmental epidemiology. Cohort studies should consider adding GLH data collection to capture historical time–activity patterns of participants, employing a "bring-your-own-location-data" citizen science approach. Privacy remains a concern that needs to be carefully managed when using GLH data. https://doi.org/10.1289/EHP10829
How similar is covid-19 to the flu?
Authors: Chris Stokel-Walker
Journal: BMJ (2022)

CORONAVIRUSHow similar is covid-19 to the flu?Chris Stokel-Walker asks whether what we've learnt about covid-19 makes the comparison to influenza fair and correct Chris Stokel-Walker, How have people compared covid-19 and influenza?For those who sought to downplay the severity of the disease caused by SARS-CoV-2, "just like the flu" was a way to express how they thought that lockdown measures were over the top.
Multimodal machine learning in precision health: A scoping review
Authors: Adrienne Kline, Hanyin Wang, Yikuan Li, Saya Dennis, Meghan Hutch, Zhenxing Xu, Fei Wang, Feixiong Cheng, Yuan Luo
Journal: npj Digital Medicine (2022)

Abstract Machine learning is frequently being leveraged to tackle problems in the health sector including utilization for clinical decision-support. Its use has historically been focused on single modal data. Attempts to improve prediction and mimic the multimodal nature of clinical expert decision-making has been met in the biomedical field of machine learning by fusing disparate data. This review was conducted to summarize the current studies in this field and identify topics ripe for future research. We conducted this review in accordance with the PRISMA extension for Scoping Reviews to characterize multi-modal data fusion in health. Search strings were established and used in databases: PubMed, Google Scholar, and IEEEXplore from 2011 to 2021. A final set of 128 articles were included in the analysis. The most common health areas utilizing multi-modal methods were neurology and oncology. Early fusion was the most common data merging strategy. Notably, there was an improvement in predictive performance when using data fusion. Lacking from the papers were clear clinical deployment strategies, FDA-approval, and analysis of how using multimodal approaches from diverse sub-populations may improve biases and healthcare disparities. These findings provide a summary on multimodal data fusion as applied to health diagnosis/prognosis problems. Few papers compared the outputs of a multimodal approach with a unimodal prediction. However, those that did achieved an average increase of 6.4% in predictive accuracy. Multi-modal machine learning, while more robust in its estimations over unimodal methods, has drawbacks in its scalability and the time-consuming nature of information concatenation.
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population
Authors: Fang Zhu, Frank J. Wolters, Amber Yaqub, Maarten J.G. Leening, Mohsen Ghanbari, Eric Boersma, M. Arfan Ikram, Maryam Kavousi
Journal: JACC Heart Failure (2022)

Amyloid-β (Aβ) may be related to cardiac function. However, there are limited data on the association of plasma Aβ with cardiac function and risk of heart failure (HF) in the general population. This study sought to determine the associations of plasma amyloid-β40 (Aβ40) and amyloid-β42 (Aβ42) with echocardiographic measurements of cardiac dysfunction and with incident HF in the general population. The study included 4,156 participants of the population-based Rotterdam Study (mean age: 71.4 years; 57.1% women), who had plasma Aβ samples collected between 2002 and 2005 and had no established dementia and HF at baseline. Multivariable linear regression models were used to explore the cross-sectional association of plasma Aβ with echocardiographic measures. Participants were followed up until December 2016. Cox proportional hazards models were used to assess the association of Aβ levels with incident HF. Models were adjusted for cardiovascular risk factors. A per 1-SD increase in log-transformed plasma Aβ40 was associated with a 0.39% (95% CI: −0.68 to −0.10) lower left ventricular ejection fraction and a 0.70 g/m2 (95% CI: 0.06-1.34) larger left ventricular mass indexed by body surface area. Aβ42 was not significantly associated with echocardiographic measures cross-sectionally. During follow-up (median: 10.2 years), 472 incident HF cases were identified. A per 1-SD increase in log-transformed Aβ40 was associated with a 32% greater risk of HF (HR: 1.32; 95% CI: 1.15-1.51), and the association was significant in men, but not in women. Higher plasma Aβ42 levels were associated with an increased risk of HF (HR: 1.12; 95% CI: 1.02-1.24), although the association was attenuated after further adjustment for concomitant Aβ40 (HR: 1.03; 95% CI: 0.92-1.16). Higher levels of Aβ40 were associated with worse cardiac function and higher risk of new onset HF in the general population, in particular among men.
Fungal microbiota dynamics and its geographic, age and gender variability in patients with cystic fibrosis
Authors: Sara Martínez-Rodríguez, Vicente Friaza, Rosa M. Girón-Moreno, Esther Quintana Gallego, Antonio Salcedo-Posadas, Joan Figuerola-Mulet, Amparo Solé-Jover, Elena Campano, Ruben Morilla, Enrique J. Calderón, Francisco J. Medrano, Carmen de la Horra
Journal: Clinical Microbiology and Infection (2022)
Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis
Authors: Emilie Audouard, Fanny Michel, Vanessa Pierroz, Taeuk Kim, Lisa Rousselot, Béatrix Gillet-Legrand, Gaëlle Dufayet-Chauffaut, Peter Buchmann, Michael Florea, Alexander Khel, Kamilya Altynbekova, Claudia Delgaldo, Encarna Escudero, Alejandra Ben Aissa Soler, Nathalie Cartier, Francoise Piguet, Marc Folcher
Journal: Journal of Controlled Release (2022)

Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.
Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential
Authors: Hubert Krukowski, Sophie Valkenburg, Avra-Melina Madella, Johan Garssen, Jeroen van Bergenhenegouwen, Saskia Adriana Overbeek, Geert R. B. Huys, Jeroen Raes, Griet Glorieux
Journal: Nature Reviews Nephrology (2022)
The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity
Authors: Sabelo Lukhele, Diala Abd Rabbo, Mengdi Guo, Jian Shen, Heidi J. Elsaesser, Rene Quevedo, Madeleine Carew, Ramy Gadalla, Laura M. Snell, Lawanya Mahesh, M. Teresa Ciudad, Bryan E. Snow, Annick You-Ten, Jillian Haight, Andrew Wakeham, Pamela S. Ohashi, Tak W. Mak, Weiguo Cui, Tracy L. McGaha, David G. Brooks
Journal: Immunity (2022)
Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases
Authors: Andreas Czosseck, Max M. Chen, Helen Nguyen, Annette Meeson, Chuan-Chih Hsu, Chien-Chung Chen, Thomashire A. George, Shu-Chian Ruan, Yuan-Yuan Cheng, Po-Ju Lin, Patrick C.H. Hsieh, David J. Lundy
Journal: Journal of Controlled Release (2022)
Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction
Authors: Huajun Zhao, Yating Yu, Yucan Wang, Lianhui Zhao, Ailu Yang, Yifei Hu, Zhaoyi Pan, Zixuan Wang, Jiarui Yang, Qiuju Han, Zhigang Tian, Jian Zhang
Journal: Cellular and Molecular Immunology (2022)
Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sjögren’s syndrome
Authors: Yanxia Wei, Na Peng, Chong Deng, Futao Zhao, Jie Tian, Yuan Tang, Sulan Yu, Yacun Chen, Yu Xue, Fan Xiao, Yingbo Zhou, Xiaomei Li, Hejian Zou, Ke Rui, Xiang Lin, Liwei Lu
Journal: Cellular and Molecular Immunology (2022)
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
Authors: Arun J. Sanyal, Julie Foucquier, Zobair M. Younossi, Stephen A. Harrison, Philip N. Newsome, Wah-Kheong Chan, Yusuf Yilmaz, Victor De Ledinghen, Charlotte Costentin, Ming-Hua Zheng, Vincent Wai-Sun Wong, Magdy Elkhashab, Ryan S. Huss, Robert P. Myers, Marine Roux, Aymeric Labourdette, Marie Destro, Céline Fournier-Poizat, Véronique Miette, Laurent Sandrin, Jérôme Boursier
Journal: Journal of Hepatology (2022)
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Authors: Fabio Campodonico, Francesca Mattioli, Carlo Introini
Journal: European Urology (2022)
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition
Authors: Franziska Erlmeier, Niklas Klümper, Laura Landgraf, Pamela L. Strissel, Reiner Strick, Danijel Sikic, Helge Taubert, Sven Wach, Carol I. Geppert, Veronika Bahlinger, Johannes Breyer, Manuel Ritter, Christian Bolenz, Florian Roghmann, Philipp Erben, Kristina Schwamborn, Ralph M. Wirtz, Thomas Horn, Bernd Wullich, Michael Hölzel, Arndt Hartmann, Jürgen E. Gschwend, Wilko Weichert, Markus Eckstein
Journal: European Urology (2022)

The value of programmed cell death ligand-1 (PD-L1) to predict durable responses to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) is inconsistent. We hypothesize that the use of archived primary tumor material (PRIM) for PD-L1 testing in clinical trials not properly reflecting the metastatic disease status (MET) contributes to this clinical issue. To analyze the predictive and prognostic value of PD-L1, spatial immunephenotypes, and major histocompatibility complex class I (MHC-I) determined in patient-matched PRIM/MET. PD-L1, spatial immunephenotypes, and MHC-I were examined in 154 mUC patients with at least one available pretreatment MET (138 patient-matched PRIM/MET pairs). PD-L1, spatial immunephenotype, and MHC-I status of (patient-matched PRIM and) pretreatment MET were correlated with chemotherapy and ICI response and outcomes. Discordance rates in patient-matched PRIM/MET were 25/30%, 36%, and 49% for PD-L1 (CPS10/IC5%), immunephenotypes, and MHC-I (loss vs preserved), respectively. Correlations with chemotherapy and ICI responses were observed for immunephenotypes and MHC-I status determined in MET (not for PD-L1 alone), but not in PRIM. In case of ICIs, patients with cytotoxic tumor immune microenvironment (TIME) showed durable responses with disease control rates of 90% and a hazard ratio for disease progression/death of 0.05 (95% confidence interval: 0.01-0.65) versus patients with immunedepleted MET (disease control rate 29%). MET MHC-I status added an incremental value to predict durable ICI responses. Limitations include the partly retrospective design and the lack of MET multisampling on individual patient level. The TIME is subject to substantial dynamics during metastatic evolution. MET immunephenotypes and MHC-I statuses show promising potential to predict chemotherapy and durable ICI responses, while the PRIM TIME does not. Thus, future clinical trials should rather rely on pretreatment MET biopsies reflecting the current immunological disease state than on PRIM. Prediction of chemotherapy and responses to immune checkpoint inhibitors might be possible using representative pretreatment metastatic biopsies.
Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)
Authors: Andreas Hiester, Yue Che, Achim Lusch, Oliver Kuß, Günter Niegisch, Anja Lorch, Christian Arsov, Peter Albers
Journal: European Urology (2022)
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: A. Vogel, J. Bridgewater, J. Edeline, R.K. Kelley, H.J. Klümpen, D. Malka, J.N. Primrose, L. Rimassa, A. Stenzinger, J.W. Valle, M. Ducreux
Journal: Annals of Oncology (2022)
An artificial LAMA2-GelMA hydrogel microenvironment for the development of pancreatic endocrine progenitors
Authors: Yan Huang, Yang Xu, Jiachen Zhu, Jian Wan, Yicheng Xiong, Zhaoyan Jiang, Shajun Zhu, Qingsong Guo, Yuxi Li, Yuhua Lu, Bin Yu, Yibing Guo, Zhiwei Wang, Yumin Yang
Journal: Biomaterials (2022)
Association of State Share of Nonphysician Practitioners With Diagnostic Imaging Ordering Among Emergency Department Visits for Medicare Beneficiaries
Authors: Eric W. Christensen, Chi-Mei Liu, Richard Duszak, Joshua A. Hirsch, Timothy L. Swan, Elizabeth Y. Rula
Journal: JAMA Network Open (2022)

The use of nonphysician practitioners (NPPs) in the emergency department (ED) continues to expand, yet little is known about associations between NPPs and ED imaging use.To investigate whether the state share of ED visits for which an NPP was the clinician of record is associated with imaging studies ordered, given that state NPP share is associated with state-level NPP scopes of practice.This cross-sectional study compared diagnostic imaging ordering patterns associated with ED visits based on 2005-2020 Medicare claims for a nationally representative 5% sample of fee-for-service beneficiaries. For all 50 states and the District of Columbia, the state NPP share of ED visits by year was used to represent state-specific practice patterns for NPPs and physicians and how those patterns have evolved over time. The analysis controlled for patient demographic characteristics, Charlson Comorbidity Index scores, ED visit severity, year, and principal diagnosis.The share of ED visits in each state in each year (state share) for which an NPP was the evaluation and management clinician.The main outcomes were the number and modality of imaging studies associated with ED visits. Analyses were by logistic regression and generalized linear model with γ-distribution and log-link function.Among 16 922 274 ED visits, 60.0% involved women, and patients' mean (SD) age was 70.3 (16.1) years. The share of all ED visits with an NPP as the clinician increased from 6.1% in 2005 to 16.6% in 2020. Compared with no NPPs, the presence of NPPs in the ED was associated with 5.3% (95% CI, 5.1%-5.5%) more imaging studies per ED visit, including a 3.4% (95% CI, 3.2%-3.5%) greater likelihood of any imaging order per ED visit and 2.2% (95% CI, 2.0%-2.3%) more imaging studies ordered per visit involving imaging.In this study, use of NPPs in the ED was associated with higher imaging use compared with the use of only physicians in the ED. Although expanded use of NPPs in the ED may improve patient access, the costs and radiation exposure associated with more imaging warrants additional study.
Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China
Authors: Yadi Zheng, Xuesi Dong, Jiang Li, Chao Qin, Yongjie Xu, Fei Wang, Wei Cao, Changfa Xia, Yiwen Yu, Liang Zhao, Zheng Wu, Zilin Luo, Wanqing Chen, Ni Li, Jie He
Journal: JAMA Network Open (2022)

Importance Although current guidelines highlight the need for earlier screening in women at increased risk of breast cancer in China, data on risk-adapted starting ages of screening are limited. Objective To explore the risk-adapted starting age of breast cancer screening in China, with comprehensive consideration of breast cancer risk factors. Design, Setting, and Participants A multicenter community-based cohort study was conducted under the framework of the Cancer Screening Program in Urban China. Data were collected from January 1, 2013, to December 31, 2018, for unscreened community-dwelling women aged 40 to 74 years without a history of cancer, kidney dysfunction, or severe heart, brain, or lung disease. Data analysis was performed from October 1, 2021, to August 16, 2022. Exposures Baseline characteristics associated with breast cancer, including first-degree family history of breast cancer, benign breast disease, breastfeeding, age at menarche, and body mass index. Main Outcomes and Measures Outcomes included breast cancer diagnosis and age at diagnosis. Risk-adapted starting age of screening was defined as the age at which women with different levels of breast cancer risk attained a 10-year cumulative risk level similar to women aged 50 years in the general population. Results Of the 1 549 988 women enrolled in this study, 3895 had breast cancer (median follow-up, 4.47 [IQR, 3.16-6.35] years). Participants were divided into different risk groups according to breast cancer risk scores (driven by risk factors including first-degree family history of breast cancer, benign breast disease, breastfeeding, age at menarche, and body mass index). Using the 10-year cumulative risk of breast cancer at age 50 years in the general population as a benchmark (2.65% [95% CI, 2.50%-2.76%]), the optimal starting age of screening for women with high, medium, or low risk of breast cancer was identified as 43, 48, or after 55 years, respectively. An online calculator was developed to calculate an individual’s optimal starting age of screening. Conclusions and Relevance This study identifies the risk-adapted starting age of breast cancer screening based on the principle of equal management of equal risks, which may inform updates of current screening guidelines.
An Overview of Telehealth in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association
Authors: Edwin A. Takahashi, Lee H. Schwamm, Opeolu M. Adeoye, Olamide Alabi, Eiman Jahangir, Sanjay Misra, Carolyn H. Still
Journal: Circulation (2022)

Telehealth enables the remote delivery of health care through telecommunication technologies and has substantially affected the evolving medical landscape. The COVID-19 pandemic accelerated the utilization of telehealth as health care professionals were forced to limit face-to-face in-person visits. It has been shown that information delivery, diagnosis, disease monitoring, and follow-up care can be conducted remotely, resulting in considerable changes specific to cardiovascular disease management. Despite increasing telehealth utilization, several factors such as technological infrastructure, reimbursement, and limited patient digital literacy can hinder the adoption of remote care. This scientific statement reviews definitions pertinent to telehealth discussions, summarizes the effect of telehealth utilization on cardiovascular and peripheral vascular disease care, and identifies obstacles to the adoption of telehealth that need to be addressed to improve health care accessibility and equity.
Single-cell immune profiling reveals thymus-seeding populations, T cell commitment, and multilineage development in the human thymus
Authors: Martijn Cordes, Kirsten Canté-Barrett, Erik B. van den Akker, Federico A. Moretti, Szymon M. Kiełbasa, Sandra A. Vloemans, Laura Garcia-Perez, Cristina Teodosio, Jacques J. M. van Dongen, Karin Pike-Overzet, Marcel J. T. Reinders, Frank J. T. Staal
Journal: Science Immunology (2022)

T cell development in the mouse thymus has been studied extensively, but less is known regarding T cell development in the human thymus. We used a combination of single-cell techniques and functional assays to perform deep immune profiling of human T cell development, focusing on the initial stages of prelineage commitment. We identified three thymus-seeding progenitor populations that also have counterparts in the bone marrow. In addition, we found that the human thymus physiologically supports the development of monocytes, dendritic cells, and NK cells, as well as limited development of B cells. These results are an important step toward monitoring and guiding regenerative therapies in patients after hematopoietic stem cell transplantation.